BioSpace News Archive

Global Blood Therapeutics, Inc. announced the European Commission has granted Marketing Authorization for Oxbryta® for the treatment of hemolytic anemia due to sickle cell disease in adult and pediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced that management will present at two upcoming investor conferences.

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, February 24, 2022, at 8:00 a.m. ET to provide a corporate update and results for the fourth quarter and full year 2021.

ImmuCell Corporation expects to report unaudited financial results for the quarter and year ended December 31, 2021 after the market closes on Tuesday, February 22, 2022.

Cerevel Therapeutics today announced it will report fourth quarter 2021 financial results on Tuesday, March 1, 2022, before the U.S. financial markets open.

SwanBio Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead candidate, SBT101, for the treatment of adrenomyeloneuropathy (AMN).

Investment agreement strengthens the strategic alliance between the two companies while supporting ITM in further developing its radiopharmaceutical pipeline and footprint in Asia.

IsoPlexis Corporation today announced it will report financial results for the fourth quarter and full year 2021 before market open on Wednesday, March 2, 2022.

Bristol Myers Squibb (NYSE: BMY) today announced that VALOR-HCM, the Phase 3 randomized, double-blind, placebo-controlled study evaluating mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy (obstructive HCM) who are eligible for septal reduction therapy (SRT), met its primary endpoint at Week 16.

Enanta Pharmaceuticals, Inc. today announced that it has dosed the first subject in its Phase 1 clinical trial of EDP-235, a coronavirus 3CL protease inhibitor (also known as the main coronavirus protease, or Mpro) specifically designed as a once-daily, oral treatment for COVID-19.